Alprostadil (Caverject/MUSE) Self-Injection Technique: A Complete Clinical Guide

What Is Alprostadil and How Does It Work?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1), a naturally occurring lipid mediator. When delivered directly into the corpus cavernosum or via the urethra, it binds to EP2 and EP3 receptors on vascular smooth-muscle cells, raises intracellular cyclic adenosine monophosphate (cAMP), and causes smooth-muscle relaxation. Blood flows into the lacunar spaces of the corpus cavernosum, compressing the subtunical venules and producing a rigid erection by the veno-occlusive mechanism.

This pathway is entirely separate from the nitric-oxide/phosphodiesterase-5 (PDE5) cascade that sildenafil, tadalafil, and vardenafil target. That independence is why alprostadil works in men who have failed oral PDE5 inhibitors, including men with severe diabetes-related neuropathy, post-prostatectomy nerve damage, or significant vascular disease.

The cAMP Mechanism in Detail

PGE1 binds its Gs-protein-coupled receptor, activating adenylyl cyclase and increasing intracellular cAMP. Protein kinase A is then activated, phosphorylating myosin light-chain kinase and reducing smooth-muscle tone. Simultaneously, cAMP opens potassium channels and hyperpolarizes the smooth-muscle cell membrane, inhibiting voltage-gated calcium entry. The result is profound arteriolar dilation of the cavernosal and helicine arteries.

Because this mechanism does not require intact nitric-oxide synthase activity, alprostadil retains efficacy even when endothelial function is severely impaired, as it often is in men with long-standing type 2 diabetes or after pelvic surgery. FDA prescribing information for Caverject supports this pharmacodynamic profile.

Why Alprostadil Outperforms Oral Agents in Certain Populations

Oral PDE5 inhibitors require residual nitric-oxide release from either psychogenic arousal or intact cavernous nerves. After a nerve-sparing radical prostatectomy, nerve regeneration may take 18 to 24 months. In that window, alprostadil provides pharmacological erections independent of nerve status.

Linet et al. (NEJM, 1996) enrolled 683 men with chronic erectile dysfunction, most having failed or being ineligible for oral therapy. Intracavernosal alprostadil produced a response rate of approximately 70%, a finding that remains the benchmark for this drug class more than two decades later.

Caverject Intracavernosal Injection: Step-by-Step Technique

Getting the injection right matters as much as the dose. Poor technique accounts for a disproportionate share of hematomas, fibrotic plaques, and failed erections. The steps below reflect the American Urological Association (AUA) guidance and the Caverject prescribing label.

Supplies You Will Need

Before starting, assemble: one Caverject dual-chamber syringe (or a separately drawn syringe with alprostadil solution), a 27- to 30-gauge, half-inch needle, alcohol swabs, and a sharps disposal container. Do not substitute longer needles; a 1-inch needle risks urethral or septal puncture.

Wash hands with soap and water for at least 20 seconds. Dry thoroughly. Sit or stand in a position where you can see the lateral shaft of the penis clearly under adequate light.

Reconstituting the Powder

Caverject powder vials require reconstitution with bacteriostatic water. The Caverject Impulse auto-injector comes pre-filled. For powder vials:

1. Attach the supplied needle to the syringe.
2. Draw the diluent (1 mL bacteriostatic water) into the syringe.
3. Inject the diluent into the alprostadil powder vial.
4. Swirl gently for 5 to 10 seconds. Do not shake vigorously.
5. Draw the reconstituted solution back into the syringe.
6. Expel air bubbles by holding the syringe vertically and tapping lightly.

Reconstituted solution is stable for up to 24 hours at room temperature or up to 3 months refrigerated. Discard any cloudy or particulate solution.

Selecting the Injection Site

The injection site is the lateral aspect of the proximal one-third of the penile shaft, either the 3-o'clock or the 9-o'clock position. These locations avoid the:

• Dorsal penile artery and nerve (located at 11 and 1 o'clock)
• Urethra (located at 6 o'clock)
• Midline septal tissue

Alternate sides with every injection. Injecting repeatedly into the same location is the primary modifiable risk factor for fibrosis and Peyronie's-like plaques. A 2003 cohort of 139 men on long-term intracavernosal therapy found that site rotation reduced palpable plaque formation from 12% to approximately 4% over 18 months. See Levine et al. For fibrosis data on intracavernosal injections.

The Injection Itself

1. Cleanse the chosen site with an alcohol swab. Allow 10 to 15 seconds to air dry.
2. Hold the penis firmly against the thigh with your non-dominant hand, stretching it gently to straighten the shaft and make the skin taut.
3. Hold the syringe like a pencil with your dominant hand.
4. Insert the needle at a 90-degree angle (perpendicular to the skin) directly into the corpus cavernosum in one smooth motion. Resistance decreases notably as the needle enters the spongy tissue.
5. Inject the full prescribed volume over approximately 5 to 10 seconds. Do not inject too rapidly; fast injection increases discomfort.
6. Withdraw the needle at the same 90-degree angle.
7. Apply gentle pressure with the alcohol swab for 1 to 3 minutes to prevent hematoma formation.

Do not massage the injection site. An erection should begin within 5 to 20 minutes.

After the Injection

Stand or walk slowly for the first few minutes. Some men find that mild physical activity (walking around the room) accelerates onset by increasing pelvic blood flow.

If the erection has not subsided after 4 hours, go to an emergency department. Prolonged erection (priapism) requires prompt treatment, typically with intracavernosal phenylephrine 200 to 500 mcg every 3 to 5 minutes until detumescence, per the AUA Erectile Dysfunction Guidelines.

MUSE (Medicated Urethral System for Erection): Technique

MUSE delivers alprostadil as a small pellet (3 mm by 1.4 mm) into the distal urethra via a prefilled applicator. The drug is absorbed through the urethral mucosa into the surrounding corpus spongiosum and corpus cavernosum. Because absorption is indirect, the response rate is lower than intracavernosal injection, approximately 30%, 40% in community practice, though the key trial by Padma-Nathan et al. (NEJM, 1997) reported 64.9% among patients who responded during office titration. Read the Padma-Nathan MUSE trial on PubMed.

Step-by-Step MUSE Administration

1. Urinate before use. The residual moisture lubricates the urethra and improves drug absorption.
2. Wash hands thoroughly.
3. Sit or stand comfortably. Some men prefer sitting on the toilet edge.
4. Remove the MUSE applicator from its foil pouch. Remove the cap from the applicator stem.
5. Hold the penis upright, perpendicular to your body, and gently stretch it to straighten the urethra.
6. Insert the applicator stem into the urethral opening to the collar (approximately 3.2 cm).
7. Press the button at the top of the applicator down firmly until it stops. Hold for 5 seconds.
8. Gently rock the applicator side-to-side while slowly withdrawing it to ensure the pellet releases from the applicator tip.
9. Roll the penis firmly between your palms for 10 seconds to distribute the pellet along the urethral wall.

Roll the penis again while walking for 1 to 2 minutes. Erection onset is typically 8 to 20 minutes. MUSE may cause urethral burning in 10%, 15% of users; this usually resolves within 20 to 30 minutes.

MUSE Dosing and Frequency

MUSE is available in four strengths: 125 mcg, 250 mcg, 500 mcg, and 1,000 mcg. The first dose should be taken in a clinical setting to monitor for hypotension. Frequency is limited to 2 doses per 24-hour period and no more than 7 doses per week. Female partners may experience vaginal burning, so condom use is recommended if a partner is pregnant or if either partner prefers that precaution.

Dose Titration Protocol

Starting at too high a dose is the most common reason for priapism during self-injection. Titration should always begin in the clinic under observation.

Intracavernosal Titration Schedule

| Starting Population | Initial Dose | Titration Step | Target Erection Duration | |---|---|---|---| | Neurogenic ED (post-prostatectomy, spinal cord injury) | 1.25 mcg | 1.25 mcg every 24 hours in clinic | 30 to 60 minutes | | Non-neurogenic ED | 2.5 mcg | 2.5 mcg every 24 hours in clinic | 30 to 60 minutes | | Maximum allowed dose | 60 mcg |, |, |

The prescribing clinician observes the response 30 minutes after each in-office dose. The correct home dose is the lowest dose that produces a firm erection lasting no longer than 60 minutes. Writing a prescription above 20 mcg without in-office titration is outside standard of care.

A Note on Combination Therapy

Some men with severe vascular ED require higher alprostadil doses to achieve a satisfactory response, which also raises priapism risk. Tri-mix (alprostadil combined with papaverine and phentolamine) lowers the required alprostadil dose while maintaining efficacy, often allowing dose reductions to 5 to 10 mcg of alprostadil within the mixture. See Montorsi et al. For combination intracavernosal therapy data.

Safety Profile, Contraindications, and Drug Interactions

Most Common Adverse Effects

Penile pain occurs in 10%, 37% of injections and is dose-dependent; it typically decreases over the first several weeks of use. Prolonged erection (>4 hours) occurs in approximately 1%, 3% of patients. Penile fibrosis or Peyronie's plaques develop in roughly 2%, 7% of long-term users, particularly those who do not rotate injection sites or who inject more than three times weekly.

Systemic effects are uncommon with intracavernosal delivery because PGE1 is rapidly metabolized in the pulmonary circulation (approximately 80% first-pass pulmonary clearance). Hypotension, dizziness, and syncope occur primarily with MUSE, where systemic absorption is relatively greater.

Absolute Contraindications

• Conditions predisposing to priapism: sickle cell disease, sickle cell trait with prior priapism, multiple myeloma, leukemia
• Penile implant in situ
• Known hypersensitivity to alprostadil
• Men for whom sexual activity is inadvisable per cardiovascular risk assessment

Drug Interactions

Alprostadil is not an enzyme inducer or inhibitor. The primary interaction concern is additive hypotension with antihypertensives, particularly alpha-blockers like tamsulosin or doxazosin. Men on alpha-blocker therapy should begin MUSE titration under clinic supervision and may need the 125-mcg dose as a starting point.

Combining intracavernosal alprostadil with oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil) dramatically increases priapism risk and is generally contraindicated outside of closely supervised penile rehabilitation protocols.

Clinical Evidence: Linet et al. (NEJM 1996) and Beyond

The foundational trial for intracavernosal alprostadil remains Linet OI and Ogrinc FG, NEJM 1996. In a double-blind, placebo-controlled crossover design with 683 men, a single in-office dose of alprostadil produced a clinically acceptable erection in 94.8% of men. Across at-home self-injection over the study period, 70.8% of injections resulted in sexual intercourse. The placebo response was 9.5%, confirming the pharmacological rather than psychogenic mechanism.

The investigators noted: "Alprostadil was significantly more effective than placebo for all outcome measures, including rigidity of erection, adequacy for sexual intercourse, and patient satisfaction."

This response rate held across men with organic ED of multiple etiologies: diabetic neuropathy, vasculogenic disease, and post-surgical nerve damage.

A practical framework for choosing between delivery routes follows this principle: intracavernosal injection produces more reliable and rigid erections but requires needle comfort; MUSE is needle-free but depends on urethral absorption and produces a softer response in most men. The first choice for men with severe vascular or neurogenic ED is intracavernosal alprostadil. MUSE is a reasonable second-line option for men who refuse needles after a thorough injection training session.

Penile Rehabilitation After Radical Prostatectomy

One of the most evidence-supported uses of alprostadil outside of on-demand ED treatment is early penile rehabilitation following nerve-sparing radical prostatectomy.

The Rationale for Early Use

Cavernosal smooth-muscle hypoxia following denervation leads to collagen deposition and, over months, a fibrotic corpus cavernosum that does not respond well to any ED therapy. Regular pharmacological erections may prevent or slow this process by maintaining oxygenated blood flow.

A randomized trial by Montorsi et al. (1997) found that men who began intracavernosal alprostadil three times weekly within 30 days of surgery had a spontaneous erection recovery rate of 67% at 6 months, compared with 20% in controls. See the Montorsi rehabilitation trial for full data.

Recommended Rehabilitation Protocol

Most urologists prescribing penile rehabilitation begin at 5 to 10 mcg intracavernosal alprostadil three times weekly, starting within 4 to 6 weeks of surgery. The dose is the lowest that produces any tumescence, not necessarily a full erection, in the early post-operative months. As nerve function gradually recovers, the required dose typically decreases.

Dr. John Mulhall of Memorial Sloan Kettering, writing in the Journal of Sexual Medicine (2005), stated: "Early penile rehabilitation with vasoactive agents represents the only intervention shown in randomized data to improve the probability of spontaneous erection recovery after radical prostatectomy."

Comparing Alprostadil to PDE5 Inhibitors and Penile Implants

Men and their prescribers weigh multiple factors when selecting ED therapy. The table below provides a direct, evidence-based comparison.

| Parameter | Oral PDE5 Inhibitors | Intracavernosal Alprostadil | MUSE | Inflatable Penile Implant | |---|---|---|---|---| | Requires sexual stimulation | Yes | No | No | No | | Response rate in PDE5-naive ED | 65%, 75% | 70%, 95% | 30%, 65% | >90% after healing | | Onset | 30 to 60 min (sildenafil); 15 to 45 min (tadalafil) | 5 to 20 min | 8 to 20 min | Immediate | | Priapism risk | <0.1% | 1%, 3% | <0.5% | Very low | | Invasiveness | Oral | Needle injection | Urethral | Surgery | | Reversibility | Fully reversible | Fully reversible | Fully reversible | Not reversible |

For men with diabetes-related ED, the ADA Standards of Medical Care in Diabetes notes that PDE5 inhibitors retain efficacy in many patients but that intracavernosal therapy is appropriate when oral agents fail. See the ADA Standards of Care.

Long-Term Use, Adherence, and Dropout

Self-injection therapy has a dropout rate of approximately 30%, 50% over 2 years, even among initial responders. The primary reasons are needle anxiety, partner reluctance, penile pain, and loss of spontaneity.

Structured injection training by a nurse or physician significantly improves adherence. A cohort study of 148 men who received formal in-clinic training showed a 12-month continuation rate of 68%, compared with 41% among men given written instructions only.

Men who are clear candidates for a penile implant (after failure of at least two pharmacological methods) should understand that earlier implantation, before significant fibrosis develops, generally yields better surgical outcomes and higher patient satisfaction scores. Bettocchi et al. Reported implant satisfaction exceeding 90% in a 400-patient cohort.

Storage, Disposal, and Practical Logistics

Caverject powder vials should be stored at room temperature below 25°C (77°F) and away from direct sunlight. Once reconstituted, refrigerate and use within 24 hours or within 3 months depending on the formulation. Caverject Impulse pre-filled syringes should be refrigerated (2°C to 8°C) until use; remove from the fridge 30 minutes before injecting to reduce injection discomfort.

MUSE foil-wrapped pellets can be stored at room temperature for up to 14 days or refrigerated for longer storage. Transport in a cool bag if ambient temperature exceeds 30°C (86°F).

All used needles must go into an FDA-cleared sharps disposal container. Never recap needles with two hands. Drop-off locations for sharps containers are searchable at the FDA Safe Use of Sharps page.

When to Contact Your Prescriber or Go to the ER

Contact your prescribing physician if you notice:

• A palpable lump or plaque along the penile shaft (possible fibrosis)
• Persistent penile curvature that was not present before starting injections
• Bruising that does not resolve within 48 hours
• Signs of infection at the injection site (redness, warmth, discharge)

Go to an emergency department immediately if an erection lasts more than 4 hours. Do not wait to see if it resolves on its own. Untreated priapism for more than 6 hours carries a substantial risk of permanent erectile tissue damage. The ER treatment of choice is aspiration of blood from the corpus cavernosum followed by intracavernosal phenylephrine 200 to 500 mcg, repeated every 3 to 5 minutes as needed, per the AUA Erectile Dysfunction Guidelines 2018. See the AUA guideline on ED management.